Cargando…

Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver

Detalles Bibliográficos
Autores principales:	Yan, Victoria C., Muller, Florian L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448088/ https://www.ncbi.nlm.nih.gov/pubmed/34370586 http://dx.doi.org/10.1128/AAC.01333-21

Ejemplares similares

Reply to Yan and Muller, “Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver”
por: Murakami, Eisuke, et al.
Publicado: (2021)

Remdesivir for COVID-19: Why Not Dose Higher?
por: Yan, Victoria C., et al.
Publicado: (2021)

Liver injury in remdesivir-treated COVID-19 patients
por: Zampino, Rosa, et al.
Publicado: (2020)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Anaphylaxis Due to Remdesivir
por: Hopkins, Brian J., et al.
Publicado: (2021)

Successful management of remdesivir extravasation
por: Conde-Estévez, David, et al.
Publicado: (2022)

Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola
por: Yan, Victoria C., et al.
Publicado: (2021)

Status of Remdesivir: Not Yet Beyond Question!
por: Chatterjee, Saptarshi
Publicado: (2021)

Response to: Status of Remdesivir: Not Yet Beyond Question!
por: Saha, Abinit, et al.
Publicado: (2021)

Pulmonary administration of remdesivir in the treatment of COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2020)

Bradycardia due to remdesivir: Report of two cases()
por: Cebrián Lara, Laura, et al.
Publicado: (2022)

Remdesivir for the treatment of COVID-19: author's response
por: Lee, Todd C., et al.
Publicado: (2023)

Remdesivir modifies interferon response in hospitalized COVID-19 patients
por: Murphy, Sarah L., et al.
Publicado: (2022)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
por: Nakaya, Aya, et al.
Publicado: (2022)

The impact of an antimicrobial stewardship program restriction on remdesivir prescribing
por: Zeitler, Kristen E., et al.
Publicado: (2022)

Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
por: Nakaya, Aya, et al.
Publicado: (2023)

Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia
por: Fordham, S E, et al.
Publicado: (2015)

Indian perspective of remdesivir: A promising COVID-19 drug
por: Singh, Devendra, et al.
Publicado: (2020)

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Remdesivir in moderate to severe COVID-19: A matter of time?
por: Bonazzetti, Cecilia, et al.
Publicado: (2021)

Re: Remdesivir for the treatment of COVID-19 by Lee et al.
por: Beccacece, Alessia, et al.
Publicado: (2023)

Single-cell RNA sequencing reveals atlas of dairy goat testis cells
por: Yu, Xiu-Wei, et al.
Publicado: (2021)

Does Remdesivir maintain the race in the general treatment protocol of COVID-19?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2021)

Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
por: Juneja, Kavita, et al.
Publicado: (2021)

Single-cell RNA sequencing identifies the properties of myelodysplastic syndrome stem cells
por: Liu, Yumei, et al.
Publicado: (2022)

Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Painful Blisters of Left Hand Following Extravasation of Remdesivir Infusion in COVID-19
por: Kumar, Neeraj, et al.
Publicado: (2021)

Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
por: Yoon, Jin Gu, et al.
Publicado: (2022)

Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)
por: Pallotto, Carlo, et al.
Publicado: (2021)

Higher Plant Proteins of Cyanobacterial Origin: Are They or Are They Not Preferentially Targeted to Chloroplasts?
por: Bayer, Roman G., et al.
Publicado: (2014)

Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
por: Yan, Victoria C., et al.
Publicado: (2020)

Remdesivir reduced upper respiratory tract SARS-CoV-2 viral RNA concentration in COVID-19 patients who developed pneumonitis
por: Lai, Christopher KC, et al.
Publicado: (2022)

Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing
por: Trkulja, Vladimir
Publicado: (2021)

Prediction of remdesivir resistance in COVID-19 illness: Need for development of clinical laboratory test
por: Kumar, Deepak, et al.
Publicado: (2021)

Remdesivir-associated bradycardia might be a sign of good prognosis in COVID-19 patients
por: Lucijanic, Marko, et al.
Publicado: (2022)

Single‐cell RNA sequencing infers the role of malignant cells in drug‐resistant multiple myeloma
por: Wang, He‐nan, et al.
Publicado: (2021)

Single-cell RNA sequencing analysis of liver reveals the enhanced entry and release abilities of human adenovirus F41, partially explaining acute hepatitis in children
por: Luan, Junwen, et al.
Publicado: (2022)

Clonal evolution in liver cancer at single-cell and single-variant resolution
por: Su, Xianbin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h5qc8fc881udb51s3a0c2vmvi2